drug development

There remains a controversy in scientific circles today regarding the value of lithium therapy in treating Alzheimer’s disease. Much of this stems from the fact that because the information gathered to date has originated from a multitude of differential approaches, conditions, formulations, timing and dosages of treatment, results are difficult to compare. Also, continued treatments… Read more

The anti-depressant Prozac (Fluoxetine) could be repurposed to take on one of the deadliest childhood tumours and possibly other types of cancer, scientists said. The breakthrough, led by Brunel University London, could spare young patients treatment with highly toxic cocktails of chemotherapy drugs and radiation. “Prozac has the potential to be used in children with… Read more

All neurodegenerative diseases have a common thread: the appearance of protein clumps in the brain such as amyloid-beta plaques in Alzheimer’s disease and alpha-synuclein aggregates in Parkinson’s. The root cause of this buildup has been hard to pinpoint, but Rockefeller scientists have identified a likely culprit that opens up a new avenue for developing treatments… Read more

Scientists at Imperial College London have gazed inside the brain to show how taking DMT alters human consciousness by considerably changing the brain’s electrical activity. DMT (or dimethyltryptamine) is one of the main psychoactive constituents in ayahuasca, the psychedelic brew traditionally made from vines and leaves of the Amazon rainforest. The drink is typically prepared… Read more

This past March, Canada’s department of health changed the way it handles the huge amount of data that companies submit when seeking approval for a new drug, biological treatment, or medical device — or a new use for an existing one. For the first time, Health Canada is making large chunks of this information publicly… Read more